small molecule

XOFLUZA

BALOXAVIR MARBOXIL

Loss of exclusivityOctober 2039latest FDA-listed patent expiry

CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand name	XOFLUZA
Active ingredient	BALOXAVIR MARBOXIL
Strength	80MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	March 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12064438	October 2039	product
11261198	September 2038	product
10759814	August 2037	substance, product
11306106	August 2037	use U-3000
10633397	April 2036	use U-2816
10392406	April 2036	substance
8987441	October 2032	substance, product
8927710	May 2031	product
9815835	June 2030	product

Regulatory exclusivity

Code	Expires
M-187	December 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Genentech